These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19488607)

  • 1. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen.
    Lima LM; Wiernsperger N; Kraemer-Aguiar LG; Bouskela E
    Clinics (Sao Paulo); 2009 May; 64(5):415-20. PubMed ID: 19488607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
    Malin SK; Nightingale J; Choi SE; Chipkin SR; Braun B
    Obesity (Silver Spring); 2013 Jan; 21(1):93-100. PubMed ID: 23505172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
    Kraemer de Aguiar LG; Laflor CM; Bahia L; Villela NR; Wiernsperger N; Bottino DA; Bouskela E
    Diabet Med; 2007 Mar; 24(3):272-9. PubMed ID: 17263761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
    Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
    BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome: A randomized placebo-controlled trial.
    Indhavivadhana S; Rattanachaiyanont M; Wongwananurak T; Techatraisak K; Jirattigalachote A; Dangrat C
    J Obstet Gynaecol Res; 2020 Jul; 46(7):1193-1202. PubMed ID: 32342619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metformin hydrochloride ameliorates adiponectin levels and insulin sensitivity in adolescents with metabolic syndrome].
    Liang L; Fu JF; Zou CC; Hong F; Wang CL; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Feb; 44(2):118-21. PubMed ID: 16624028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study.
    Gomez-Marcos MA; Recio-Rodríguez JI; Patino-Alonso MC; Agudo-Conde C; Gomez-Sanchez L; Rodriguez-Sanchez E; Gomez-Sanchez M; Garcia-Ortiz L
    Cardiovasc Diabetol; 2011 Oct; 10():90. PubMed ID: 21999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial.
    Ley CM; Ni Q; Liao X; Gao HL; Robinson N
    Chin J Integr Med; 2016 Oct; 22(10):728-37. PubMed ID: 27412590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
    Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
    Pruski M; Krysiak R; Okopien B
    Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
    Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
    Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
    Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG
    Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.